ATAIBECKLEY INC (9VC.DE) Stock Price, Forecast & Analysis

FRA:9VC • NL0015000DX5

3.426 EUR
-0.04 (-1.21%)
Last: Dec 30, 2025, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership

9VC.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap1.24B
Revenue(TTM)308.00K
Net Income(TTM)-149.27M
Shares363.19M
Float348.33M
52 Week High6
52 Week Low1.06
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.7
PEN/A
Fwd PEN/A
Earnings (Next)03-16
IPO2021-06-18
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
9VC.DE short term performance overview.The bars show the price performance of 9VC.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40

9VC.DE long term performance overview.The bars show the price performance of 9VC.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of 9VC.DE is 3.426 EUR. In the past month the price increased by 6.93%. In the past year, price increased by 163.44%.

ATAIBECKLEY INC / 9VC Daily stock chart

9VC.DE Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to 9VC.DE. When comparing the yearly performance of all stocks, 9VC.DE is one of the better performing stocks in the market, outperforming 96.95% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
9VC.DE Full Technical Analysis Report

9VC.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to 9VC.DE. While 9VC.DE has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
9VC.DE Full Fundamental Analysis Report

9VC.DE Financial Highlights

Over the last trailing twelve months 9VC.DE reported a non-GAAP Earnings per Share(EPS) of -0.7.


Industry RankSector Rank
PM (TTM) N/A
ROA -62.24%
ROE -93.44%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-75%
Sales Q2Q%1772.5%
EPS 1Y (TTM)0%
Revenue 1Y (TTM)-1.91%
9VC.DE financials

9VC.DE Forecast & Estimates

18 analysts have analysed 9VC.DE and the average price target is 10.49 EUR. This implies a price increase of 206.11% is expected in the next year compared to the current price of 3.426.

For the next year, analysts expect an EPS growth of 30.67% and a revenue growth 468.25% for 9VC.DE


Analysts
Analysts83.33
Price Target10.49 (206.19%)
EPS Next Y30.67%
Revenue Next Year468.25%
9VC.DE Analyst Estimates9VC.DE Analyst Ratings

9VC.DE Ownership

Ownership
Inst Owners12.45%
Ins Owners3.7%
Short Float %N/A
Short RatioN/A
9VC.DE Ownership

9VC.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
SAN SANOFI9.72198.536B
1SAN SANOFI9.72198.488B
SNW SANOFI9.72198.464B
MRK MERCK KGAA14.6455.543B
UNC UCB SA26.3452.693B
UCB UCB SA24.5349.075B
1BAYN BAYER AG-REG8.641.291B
BAYN BAYER AG-REG8.641.272B
IPN IPSEN14.4713.837B
REC RECORDATI INDUSTRIA CHIMICA16.6910.126B

Related stock screener links

View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges

About 9VC.DE

Company Profile

9VC logo image ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

Company Info

ATAIBECKLEY INC

Prof. J.H.Bavincklaan 7

Amstelveen NOORD-HOLLAND NL

Employees: 54

9VC Company Website

9VC Investor Relations

Phone: 31207932536

ATAIBECKLEY INC / 9VC.DE FAQ

What does ATAIBECKLEY INC do?

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.


What is the current price of 9VC stock?

The current stock price of 9VC.DE is 3.426 EUR. The price decreased by -1.21% in the last trading session.


Does 9VC stock pay dividends?

9VC.DE does not pay a dividend.


What is the ChartMill technical and fundamental rating of 9VC stock?

9VC.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


How is the valuation of ATAIBECKLEY INC (9VC.DE) based on its PE ratio?

ATAIBECKLEY INC (9VC.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).